3 hours Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Reaffirmed by HC Wainwright MarketBeat
HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday.
HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday.